Shenzhen Hepalink Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.
Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.
The company's financial results are due by the end of March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.